BioTuesdays

Category - Markets

Tabula Rasa HealthCare

Stifel starts Tabula Rasa HealthCare at buy

Stifel launched coverage of Tabula Rasa HealthCare (NASDAQ:TRHC) with a “buy” rating and $17 price target. The stock closed at $14.23 on Friday. Tabula is a healthcare information technology company focused on...

Xenon Pharma

Stifel starts Xenon Pharma at buy

Stifel initiated coverage of Xenon Pharmaceuticals (NASDAQ:XENE) with a “buy” rating and $18 price target. The stock closed at $8.35 on Oct. 20. Analyst Stephen Willey writes that Xenon has successfully leveraged its...

AC Immune

Leerink starts AC Immune at outperform

Leerink initiated coverage of AC Immune SA (NASDAQ:ACIU) with an “outperform” rating and $22 price target. The stock closed at $14.43 on Friday. AC Immune is focused on developing novel medicines for neurodegenerative...

BioSyent

Cormark starts BioSyent at buy

Cormark Securities initiated coverage on BioSyent (TSX-V: RX) with a “buy” recommendation and $10.25 target price. The stock closed at $8.40 on Thursday. BioSyent establishes and builds out pharmaceutical brands in the...

Kura Oncology

Leerink resumes coverage of Kura at outperform

Leerink resumed coverage of Kura Oncology (NASDAQ:KURA) with an “outperform” rating and $15 price target. The stock closed at $5.60 on Wednesday. “We view Kura’s lead pipeline program, tipifarnib (a...

Alcobra Pharmaceuticals

Stifel downgrades Alcobra to hold

Stifel downgraded Alcobra (NASDAQ:ADHD) to “hold” from “buy” and slashed its price target to $3 from $17 after the FDA issued a clinical hold on the company’s Phase 3 study of metadoxine extended release (MDX) in adult...

CRH Medical

RBC starts CRH Medical at outperform

RBC Capital Markets initiated coverage of CRH Medical (NYSE MKT:CRHM; TSX:CRH) with an “outperform” rating and price target of $6.50 (Canadian). The stock closed at $5.50 on Wednesday. Analyst Doug Miehm writes that CRH...

IRadimed

Roth downgrades iRadimed to neutral

Roth Capital Partners downgraded iRadimed (NASDAQ:IRMD) to “neutral” from “buy” with a new price target of $11.50 after the company pre-announced a third quarter miss and reduced its 2016 outlook. The stock closed at...

Sorrento Therapeutics

Roth starts Sorrento Therapeutics at buy

Roth Capital Partners launched coverage of Sorrento Therapeutics (NASDAQ:SRNE) with a “buy” rating and $15 price target. The stock closed at $7.74 on Friday. Sorrento has a proprietary fully human antibody library...